Expression level of CDX2 gene in acute myeloid leukemia and its clinical significance.
- Author:
Ying LU
1
;
Qiong WANG
;
Qi-tian MU
;
Meng-xia YU
;
Zhi-mei CHEN
;
Ji-yu LOU
;
Jie JIN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; CDX2 Transcription Factor; Case-Control Studies; Female; Homeodomain Proteins; genetics; Humans; Karyotyping; Leukemia, Myeloid, Acute; diagnosis; genetics; Male; Middle Aged; Mutation; Prognosis; Young Adult; fms-Like Tyrosine Kinase 3; genetics
- From: Chinese Journal of Hematology 2012;33(10):835-838
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the expression and clinical significance of Caudal-type homeobox transcription factor 2 (CDX2) gene in acute myeloid leukemia (AML) patients.
METHODReal time quantitative PCR (RQ-PCR) was used to test the expression level of CDX2 gene in 108 de novo AML patients and the clinical features of these patients were analyzed.
RESULTSCDX2 gene transcript levels were detectable in bone marrow mononuclear cells from 108 AML patients and 7 healthy donors, the median expression level were 1179.44 (range 14.15 - 867 961.10) and 105.30 (range 22.30 - 453.11). There was a statistically significant difference in expression level of CDX2 gene between the AML patients and normal donor (P < 0.01). All 14 patients with FLT3-ITD(+) were in CDX2 gene higher expression group (P = 0.018), including 10 patients with normal karyotype. In the 83 treated AML patients (P = 0.046) and 57 higher WBC count (≥ 10×10(9)/L, P = 0.048) patients, the higher expression level of CDX2 gene was associated with lower complete remission (CR) rates.
CONCLUSIONSHigher expression level of CDX2 gene was seen mostly in AML patients with FLT3-ITD mutation and with lower CR rates. CDX2 gene might be a prognostic molecular marker in AML patients with normal karyotype.
